Nivolumab and ipilimumab with concurrent stereotactic radiosurgery for intracranial metastases from non-small cell lung cancer: analysis of the safety cohort for non-randomized, open-label, phase I/II trial (vol 11, e006871, 2023)
D O I:
10.1136/jitc-2023-006871corr1